Moreover, our engineered anti-BCMA-CAR NK cells expressing sTRAIL demonstrate remarkable compatibility with proteasome inhibitors, which are commonly used in MM treatment. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.